ArticleOncotarget2016
miR-26a induced the suppression of tumor growth of cholangiocarcinoma via KRT19 approach.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- The Evolving Landscape of microRNAs in Cholangiocarcinoma and Pancreatic Cancer.Diagnostics (Basel, Switzerland) · 2025Review
- Application and mechanism of anticancer peptides in organoid models of intrahepatic cholangiocarcinoma.Scientific reports · 2025Article
- Screening potential biomarkers of cholangiocarcinoma based on gene chip meta-analysis and small-sample experimental research.Frontiers in oncology · 2022Article
- Aspirin inhibits cholangiocarcinoma cell proliferation via cell cycle arrest in vitro and in vivo.International journal of oncology · 2021Article
- Robust hypergraph regularized non-negative matrix factorization for sample clustering and feature selection in multi-view gene expression data.Human genomics · 2019Article
- Altered keratinocyte differentiation is an early driver of keratin mutation-based palmoplantar keratoderma.Human molecular genetics · 2019Article
- miR-26a suppresses osteosarcoma migration and invasion by directly targeting HMGA1.Oncology letters · 2018Article
- Long noncoding RNA LINC01296 promotes tumor growth and progression by sponging miR-5095 in human cholangiocarcinoma.International journal of oncology · 2018Article
- Translational Bioinformatics for Cholangiocarcinoma: Opportunities and Challenges.International journal of biological sciences · 2018Review
- NcRNAs and Cholangiocarcinoma.Journal of Cancer · 2018Review
- miRNA and lncRNA as biomarkers in cholangiocarcinoma(CCA).Oncotarget · 2017Review
- Long noncoding RNA DLX6-AS1 promotes renal cell carcinoma progression via miR-26a/PTEN axis.Cell cycle (Georgetown, Tex.) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsKRT19 was identified as one of the key biomarkers for distinguishing cholangiocarcinoma (CCA) and hepatocellular carcinoma. The detailed role of miRNAs involved in the oncogenic incident of KRT19 was poor investigated.
resultsBased on prediction and validation, miR-26a was inversely correlated with KRT19 in patients' tissues samples and biopsies. Ectopic expression of miR-26a dramatically suppressed cell proliferation and tumor growth in vitro and in vivo. Knock-down miR-26a could induce an increasing population of SP cells by promoting KRT19 expression. The KRT19 was also suppressed via directly binding at 3'UTR region by miR-26a. MATERIALS AND
methodsBioinformatics prediction was first applied to screening the potential miRNA involved. RT-PCR, Immunohistochemistry and Western blot were used to examine the expression of miRNAs and candidate genes in 65 pairs of cholangiocarcinoma. The loss-and gain-function assay was employed to detect the role of certain miRNA in vitro and vivo. Side-population (SP) cells were detected and sorted by flow cytometry.
conclusionsAberrant decreased miR-26a could promote cell proliferation by regulating KRT19 which play important roles in the pathogenesis of CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.